(Q46941679)

26 December 2017

title

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer (English)

1 reference

26 December 2017

1 reference

1 reference

Chad A Hamilton

1

1 reference

26 December 2017

G Larry Maxwell

2

1 reference

26 December 2017

Mildred R Chernofsky

3

1 reference

26 December 2017

Sarah A Bernstein

4

1 reference

26 December 2017

John H Farley

5

1 reference

26 December 2017

G Scott Rose

6

1 reference

26 December 2017

language of work or name

English

0 references

publication date

18 June 2008

1 reference

26 December 2017

published in

Gynecologic Oncology

1 reference

26 December 2017

volume

111

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

530-532

1 reference

26 December 2017

Palliation of malignant ascites

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.028

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.028

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.028

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.028

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.028

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.028

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.028

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.028

Experience with bevacizumab in the management of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.028

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.028

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.028

10.1016/J.YGYNO.2008.04.028

7 January 2021

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017